The treatment of locally advance rectal cancer is a challenging with a relatively high incidence of local recurrence. CRT, however, has proven to be a great success in controlling rectal tumor locally. Nevertheless, recognizing relevant biomarkers are of paramount importance in order to tailor patient management and to avoid unnecessary chemotherapy related morbidity. In addition, biomarkers could outline oncological outcomes early on. Tumor response considered a strong indicator about tumor status and response to the given treatment. Unfortunately, there is no single effective method to predict tumor response to CRT treatment solely. However development of clinical and immunohistochemistry markers are essential to know what it takes to design a proper management plan for the right patient. We focus in our review to summarize relevant articles emphasizing predictive value of tumor biomarker in estimating rectal cancer response to preoperative CRT.
Watch and wait in locally advance rectal cancer: Past, present and future
